Clinical trials: Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
The purpose of AROAPOC3-2001 is to evaluate the efficacy and safety of ARO-APOC3 in participants with severe hypertriglyceridemia. Participants will receive 2 subcutaneous injections of ARO-APOC3.
- Trial name
- SHASTA-2 (NCT04720534)
- Testing
- ARO-APOC3
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 229 people
- Sponsor
- Arrowhead Pharmaceuticals
Severe Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVE (NCT01242527)
- Testing
- omefas
- Where
- 68 sites in United States, Denmark and 5 more
- Volunteers
- 399 people
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
This is a randomized, open-label crossover study. The primary objective of this study is to compare the relative bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and the…
- Trial name
- ECLIPSEIV (NCT02189252)
- Testing
- Epanova, Lovaza
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia (sHTG)
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
- Trial name
- NCT03452228
- Testing
- evinacumab
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Severe Hypertriglyceridemia
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
This study is designed to assess the efficacy, safety, and tolerability of different doses and dose regimens (once weekly [QW] or every 2 weeks [Q2W]), subcutaneous (SC) dosing of BIO89-100 (pegozafermin) compared to placebo in…
- Trial name
- NCT04541186
- Testing
- Pegozafermin
- Where
- 48 sites in United States, Czechia and 2 more
- Volunteers
- 86 people
- Sponsor
- 89bio, Inc.
Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVEII (NCT02009865)
- Testing
- Epanova, Olive Oil
- Where
- 40 sites in United States, Canada and 5 more
- Volunteers
- 379 people
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat…
- Trial name
- ECLIPSE (NCT01208961)
- Testing
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia, Mixed Dyslipidaemia
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
- Trial name
- INDIGO-1 (NCT02944383)
- Testing
- Gemcabene
- Where
- 49 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Severe Hypertriglyceridemia
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients With Fasting High Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment.
- Trial name
- NCT03011450
- Testing
- K-877, Fenofibrate
- Where
- 241 sites in United States, Belarus and 7 more
- Volunteers
- 471 people
- Sponsor
- Kowa Research Institute, Inc.
Severe Hypertriglyceridemia
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
- Trial name
- NCT03001817
- Testing
- K-877, Fenofibrate
- Where
- 220 sites in United States, Belarus and 7 more
- Volunteers
- 551 people
- Sponsor
- Kowa Research Institute, Inc.
Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
The purpose of the study was to evaluate the effect of olezarsen on percent change in fasting triglyceride (TG) levels compared to placebo at Months 6 and 12 and the proportion of participants who achieve different thresholds in…
- Conditions
- Hypertriglyceridemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia
- Trial name
- NCT05355402
- Testing
- Olezarsen
- Where
- 24 sites in United States, Canada
- Volunteers
- 154 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Hypertriglyceridemia
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without familial chylomicronemia syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL)…
- Trial name
- NCT04863014
- Testing
- evinacumab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 21 people
- Sponsor
- Regeneron Pharmaceuticals